{"id":"NCT00642304","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","officialTitle":"A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously C.E.R.A. for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03-27","primaryCompletion":"2009-12-09","completion":"2009-12-09","firstPosted":"2008-03-25","resultsPosted":"2016-11-07","lastUpdate":"2018-06-26"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"methoxy polyethylene glycol-epoetin beta [C.E.R.A.]","otherNames":[]}],"arms":[{"label":"methoxy polyethylene glycol-epoetin beta","type":"EXPERIMENTAL"}],"summary":"This single arm study will assess the efficacy and safety of subcutaneous C.E.R.A. when administered for the maintenance of hemoglobin levels in participants with chronic renal anemia, not on dialysis. Participants currently receiving maintenance treatment with subcutaneous darbepoetin alfa or epoetin beta will receive monthly injections of C.E.R.A., with the starting dose (120, 200 or 300 micrograms \\[mcg\\] subcutaneously \\[SC\\]) derived from the dose of darbepoetin alfa or epoetin beta they were receiving in the week preceding study start.","primaryOutcome":{"measure":"Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy Evaluation Period (EEP)","timeFrame":"EEP (Weeks 16 to 24)","effectByArm":[{"arm":"Methoxy Polyethylene Glycol-epoetin Beta","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":23,"countries":["Netherlands"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":20},"commonTop":["Hypertension","Cystitis","Blood phosphorus increased","Blood potassium increased","Renal failure chronic"]}}